The tools we need to achieve long-term stability for community providers and ensure better outcomes for rural Americans are available, and CMS can help us utilize them.
Nearly 14% of Americans live in rural communities. For those of us in health care who work with numbers all day, it’s important to constantly remind ourselves what these figures represent. Each person who makes up that 14% is a unique individual with a name, a face, a family, and a quality of life that should be better served by the health care system.
It is no secret that some of the greatest disparities in health care today exist for those who live in rural America, where geography, lack of infrastructure, and other social factors all contribute to drastically poorer health outcomes. It’s an iniquitous reality underscored by a mortality rate that’s 23% higher for people living in rural communities than those who live in urban communities. Individuals in rural communities deserve so much more.
Recently, CMS’ Rural Health Council released its Improving Health in Rural Communities 2021 report highlighting the multiple agency initiatives over the past year. I applaud CMS for its increased focus on the needs of rural communities and its continued commitment to improving the health and well-being of those who live in rural, frontier, tribal, and geographically isolated areas.
The CMS report outlined a number of important federal programs that have facilitated better access to care for rural Americans in recent years, including:
These initiatives demonstrate incredible progress made in rural care delivery and payment, but more must be done. Namely, we must also expand access to cellular-based remote patient monitoring (RPM) to empower individuals to take action in the management of their chronic conditions. Cellular-based RPM can play a critical role in reducing spending and improving outcomes for people in rural communities who struggle with cardiovascular disease, diabetes, and other chronic conditions; devices can detect dysrhythmia, for example, and alert providers and plans in real time, giving clinicians ample time to stage a lifesaving intervention.
For many patients, this technology can be the difference between life and death. This makes RPM absolutely essential for people who live in rural communities, where the nearest hospital may be tens of miles away. But despite its massive potential to revolutionize the way we approach preventive care, its minimal usage comes down to reimbursement. Change the payment models, and we’ll incentivize providers to tap RPM’s potential with millions of patients in these communities.
We must also do more to meet people where they are. It is a popular turn of phrase within health care and beyond, but I mean it quite literally: We need to broaden the experience of health and care delivery into the day-to-day routines of individuals. We need to bring services into homes and communities, where they are most convenient and accessible. Where do people shop? Where do they socialize? That is where health care must be.
The chain clinic model has achieved success in urban and suburban communities, but we can’t count on this approach to work in rural America, where the population is geographically distributed and the nearest neighbor—much less the nearest hospital—may be tens of miles away. If we want to reach people in rural communities within the routines of their week and begin bridging critical gaps in care, we must adopt hybrid models of care that encompass partnerships with trusted community providers, mobile clinicians, virtual care, and remote patient monitoring devices.
What I’m describing is nothing short of a rearchitecting of rural health, but it’s what’s needed to get quality care to the 14% of Americans who simply do not currently have access to it. The tools we need to achieve long-term stability for community providers and ensure better outcomes for rural Americans are available to us. I encourage CMS to help us use them.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer
March 22nd 2024Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The White House has called out the Republican Study Committee’s budget proposal for backing legislation that would put restrictions on abortion access; nearly 108,000 Americans died of drug overdoses in 2022; surgeons in Boston have transplanted a kidney from a genetically engineered pig into an ailing 62-year-old man.
Read More
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More